NL-OMON37966
Not yet recruiting
Not Applicable
: Long-term follow up of growth and bone mineralization of former preterm infants - FoBoMin
niversitair Medisch Centrum Sint Radboud0 sites110 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversitair Medisch Centrum Sint Radboud
- Enrollment
- 110
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Informed consent
- •A participant of our previous study (birth at gestational age below 34 weeks, admission to the NICU of the Radboud UMC on the first day of life, expected duration of parenteral nutrition more than 5 days)
Exclusion Criteria
- •Not full filling inclusion criteria
- •At our previous study asphyxia, congenital malformation, renal and hepatic insufficiency at birth were exclusion criteria.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
ong-term follow up of growth and bone mineralization of former preterm infantsFoBoMinpreterm infantsbone mineralizationlengthNL-OMON28045Radboud University Medical Centre110
Completed
Not Applicable
ong-term observation on adult bone mineral density and lifestyle-related diseases prevention with daily lemon intake in Osakikamijima Town, Hiroshima prefectureJPRN-UMIN000025818SAPPORO HOLDINGS Ltd.170
Active, not recruiting
Phase 1
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2021-000452-19-BGObsEva S.A.400
Active, not recruiting
Phase 1
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2021-000452-19-PLObsEva S.A.400
Active, not recruiting
Phase 1
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2021-000452-19-HUObsEva S.A.400